Literature DB >> 27888053

Current Understanding of Atherogenesis.

Richard A Brown1, Eduard Shantsila2, Chetan Varma3, Gregory Y H Lip4.   

Abstract

Scientific understanding of atherogenesis is constantly developing. From Virchow's observations 160 years ago we now recognize the endothelial response to injury as inflammatory, involved in all stages of atherosclerosis. Endothelial activation may cause reversible injury or dysfunction, or lead to irreparable damage. Indeed, early atherosclerosis is reversible. The introduction of genome-wide association testing has furthered the identification of potentially important genetic variants that help explain the heritability of coronary artery disease as well as spontaneous cases of severe coronary artery disease in patients with otherwise minimal risk factors. However, the mechanisms by which many of the newer variants exert their influence remain unknown.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherogenesis; Coronary artery disease; Genetic factors; Inflammation

Mesh:

Year:  2016        PMID: 27888053     DOI: 10.1016/j.amjmed.2016.10.022

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  24 in total

Review 1.  Cardiovascular Consequences of Binge Drinking: An Integrative Review with Implications for Advocacy, Policy, and Research.

Authors:  Mariann R Piano; Adriana Mazzuco; Minkyung Kang; Shane A Phillips
Journal:  Alcohol Clin Exp Res       Date:  2017-02-13       Impact factor: 3.455

2.  YKL-40 promotes the progress of atherosclerosis independent of lipid metabolism in apolipoprotein E-/- mice fed a high-fat diet.

Authors:  Lei Chen; Jianlei Zheng; Qi Xue; Yan Zhao
Journal:  Heart Vessels       Date:  2019-05-21       Impact factor: 2.037

3.  Network Pharmacology-Based Exploration of Synergistic Mechanism of Guanxin II Formula (II) for Coronary Heart Disease.

Authors:  Song Sheng; Zhi-Xu Yang; Feng-Qin Xu; Ye Huang
Journal:  Chin J Integr Med       Date:  2020-05-09       Impact factor: 1.978

4.  The implications of neutrophil extracellular traps in the pathophysiology of atherosclerosis and atherothrombosis.

Authors:  Mostafa N Mostafa; Mahmoud Osama
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-29

5.  Myocardial Microvascular Dysfunction in Rheumatoid ArthritisQuantitation by 13N-Ammonia Positron Emission Tomography/Computed Tomography.

Authors:  Isabelle Amigues; Cesare Russo; Jon T Giles; Aylin Tugcu; Richard Weinberg; Sabahat Bokhari; Joan M Bathon
Journal:  Circ Cardiovasc Imaging       Date:  2019-12       Impact factor: 7.792

Review 6.  Advances in lipid-lowering therapy through gene-silencing technologies.

Authors:  Børge G Nordestgaard; Stephen J Nicholls; Anne Langsted; Kausik K Ray; Anne Tybjærg-Hansen
Journal:  Nat Rev Cardiol       Date:  2018-02-08       Impact factor: 32.419

Review 7.  Extracellular Vesicles as Messengers in Atherosclerosis.

Authors:  Mengna Peng; Xinfeng Liu; Gelin Xu
Journal:  J Cardiovasc Transl Res       Date:  2019-10-29       Impact factor: 4.132

8.  Osteopontin and osteoprotegerin in atherosclerotic plaque - are they significant markers of plaque vulnerability?

Authors:  Cristina Strobescu-Ciobanu; Simona Eliza Giuşcă; Irina Draga Căruntu; Cornelia Amălinei; Andreea Rusu; Elena Cojocaru; Radu Florin Popa; Cristian Dumitru Lupaşcu
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

9.  Ox-LDL Causes Endothelial Cell Injury Through ASK1/NLRP3-Mediated Inflammasome Activation via Endoplasmic Reticulum Stress.

Authors:  Liwei Hang; Yan Peng; Rui Xiang; Xiangdong Li; Zhiliang Li
Journal:  Drug Des Devel Ther       Date:  2020-02-24       Impact factor: 4.162

10.  Non-mercaptalbumin is significantly associated with the coronary plaque burden and the severity of coronary artery disease.

Authors:  Shengpu Chou; Keiko Yasukawa; Yusuke Fujino; Midori Ishibashi; Mikiko Haraguchi; Masaya Sato; Hitoshi Ikeda; Sunao Nakamura; Yutaka Yatomi
Journal:  Sci Rep       Date:  2021-07-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.